What is PT-141?
PT-141 is a synthetic peptide derived from alpha-melanocyte-stimulating hormone (α-MSH), a naturally occurring neuropeptide. Its formal generic name is bremelanotide. The brand name is Vyleesi. It was developed by Palatin Technologies and commercialized by AMAG Pharmaceuticals (later acquired by Covis Pharma).
The compound belongs to a class called melanocortin receptor agonists — a family of peptides that interact with the melanocortin system, a central nervous system signaling network involved in a wide range of functions including skin pigmentation, energy homeostasis, and sexual function. PT-141 selectively activates the MC3R and MC4R receptor subtypes, both of which are expressed in brain regions governing arousal and sexual motivation.
The FDA approved bremelanotide injection in June 2019 for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. It is the only FDA-approved medication for female sexual dysfunction that works through a central (brain-based) mechanism.
The distinction between central and peripheral mechanisms is clinically significant. Most treatments for sexual dysfunction act on the periphery — they increase blood flow, adjust hormones, or affect genital tissue directly. PT-141 is different. It acts on the desire circuitry in the brain itself. That's a fundamentally different pharmacological approach, and it means it can work even when vascular or hormonal factors are normal.
The FDA Approval Story
The path from compound to approved medication took nearly two decades and several pivots. Understanding the history explains why the drug's current form — a subcutaneous injection, not a nasal spray — looks the way it does, and why its indicated use is narrower than many early observers anticipated.
Researchers at the University of Arizona studying melanocortin peptides for tanning applications notice unexpected side effects in early trials — spontaneous erections in male participants. The compound drawing attention: PT-141's precursor, Melanotan II (MTII).
Palatin Technologies acquires rights and develops bremelanotide as a distinct, optimized compound. Early clinical work focuses on erectile dysfunction in men via intranasal delivery, with Phase 2 trials showing promise.
FDA places a clinical hold on the intranasal bremelanotide program after trials reveal transient but consistent increases in blood pressure — up to 6 mmHg systolic. Development pivots toward a subcutaneous formulation with a more controlled pharmacokinetic profile and a narrower indicated population.
Palatin refocuses development on female sexual dysfunction, particularly HSDD in premenopausal women. The RECONNECT Phase 3 program launches — two randomized, placebo-controlled trials, each enrolling over 600 women.
FDA approves Vyleesi (bremelanotide injection, 1.75 mg) for acquired, generalized HSDD in premenopausal women. AMAG Pharmaceuticals launches commercially. It becomes only the second FDA-approved treatment for female sexual dysfunction (Addyi, approved 2015, was the first).
Commercial adoption grows slowly. Compounding pharmacies begin offering PT-141 off-label in various formulations. Interest in off-label use for men and postmenopausal women expands as the compound gains traction in longevity and sexual wellness communities.
The approval carries important specificity: it is indicated for acquired (not lifelong) HSDD that is generalized (occurring regardless of partner, situation, or type of stimulation) in premenopausal women. Off-label use in postmenopausal women and men — while clinically practiced — is not supported by the FDA indication.
How It Works: Melanocortin Receptors in the Brain
The melanocortin system comprises a family of five G protein-coupled receptors (MC1R through MC5R) distributed throughout the body and central nervous system. Each subtype has distinct tissue expression and functional roles.
Sexual function is primarily governed by MC3R and MC4R, both of which are densely expressed in the hypothalamus — specifically in the medial preoptic area (MPOA) and paraventricular nucleus (PVN), regions long associated with motivation, arousal, and the initiation of sexual behavior. PT-141 agonizes both of these receptor subtypes, activating downstream signaling cascades that increase dopamine and oxytocin release in limbic circuits.
The key distinction: desire, not arousal
This is where PT-141 differs from every peripheral treatment. Desire — the subjective motivation to pursue sexual activity — is generated in the brain. Arousal (the physiological changes that follow) is mediated downstream, in peripheral tissue. Most sexual dysfunction treatments address the downstream symptoms. PT-141 acts upstream, on the motivational circuitry itself.
Think of it as a desire signal amplifier rather than a plumbing fix. It doesn't dilate blood vessels, increase lubrication directly, or modify hormone levels. It activates neural circuits that prime the brain to want sex — and the downstream physiological responses (including genital blood flow, lubrication) follow as a consequence of that central signal.
Timing and duration of effect
After subcutaneous injection, bremelanotide reaches peak plasma concentrations in approximately 60 minutes. The recommended administration window is 45 minutes before anticipated sexual activity. The half-life is approximately 2.7 hours, meaning the central effects are relatively short-lived, tapering over 4–6 hours. This as-needed dosing profile distinguishes it from daily oral medications like Addyi (flibanserin).
PT-141 also agonizes MC1R, the pigmentation receptor in skin melanocytes. This is an off-target effect that can occasionally cause mild, transient hyperpigmentation — particularly with repeated use. This is the same receptor targeted by Melanotan I and II, the cosmetic tanning peptides. It's pharmacologically related, but PT-141 is optimized for central CNS activity, not tanning.
PT-141 vs. Every Other Sexual Wellness Treatment
The therapeutic landscape for sexual dysfunction spans multiple mechanisms, delivery methods, and target populations. Understanding where PT-141 sits relative to other options requires understanding what problem each treatment actually solves.
| Treatment | Mechanism | Target | Primary Use | Status |
|---|---|---|---|---|
| PT-141 (Vyleesi) | Melanocortin MC3/4R agonist — brain-based desire activation | Hypothalamic arousal circuits | HSDD (women) | FDA Approved |
| Addyi (flibanserin) | Serotonin 5-HT1A agonist / 5-HT2A antagonist + dopamine partial agonist | Limbic system — daily oral use | HSDD (women, premenopausal) | FDA Approved |
| Viagra / Cialis (PDE5i) | Inhibits PDE5 → nitric oxide → smooth muscle relaxation → blood flow | Penile vasculature | Erectile dysfunction (men) | FDA Approved |
| Testosterone (topical/injectable) | Hormone replacement — systemic androgen levels | Androgen receptors throughout body/brain | Low libido in men; off-label women | FDA Approved (men) |
| Estrogen therapy | Hormone replacement — systemic estrogen levels | Vaginal tissue, brain, bone | Menopause symptoms, GSM, HSDD | FDA Approved |
| Ospemifene (Osphena) | Selective estrogen receptor modulator (SERM) | Vaginal epithelium | GSM / dyspareunia | FDA Approved |
| Kisspeptin | Neuropeptide activating GnRH neurons — upstream hormone signaling | Hypothalamic-pituitary axis + limbic reward | Sexual aversion (research only) | Research Phase |
| Tribulus / Maca / Ashwagandha | Various — mild androgen support, stress reduction, unclear CNS effects | Peripheral, adaptogenic | Mild libido support (supplement) | OTC Supplement |
PT-141 vs. Addyi: The brain-based comparison
Both PT-141 and Addyi (flibanserin) are FDA-approved for HSDD in premenopausal women, and both act centrally — but they are mechanistically distinct and practically very different.
Addyi requires daily oral administration for 8 weeks before efficacy is assessed, has moderate drug interactions (particularly with alcohol and CYP3A4 inhibitors), and carries a black box warning for hypotension and syncope with alcohol use. It's a daily commitment with a slow onset of therapeutic benefit.
PT-141 is taken on demand, 45 minutes before anticipated activity, with effects that resolve within hours. There's no buildup period. The side effect profile (mainly nausea and transient blood pressure changes) is acute and resolves quickly. For women who want situational intervention rather than daily medication, PT-141 offers a fundamentally different experience.
Neither is clearly "better" — they serve different clinical profiles, and some providers offer them sequentially or in tandem.
Clinical Trial Data: Women
The FDA approval for Vyleesi was based primarily on two Phase 3 randomized, double-blind, placebo-controlled trials conducted under the RECONNECT program (Studies 301 and 302). Together, they enrolled approximately 1,267 premenopausal women diagnosed with acquired, generalized HSDD.
RECONNECT trial design
Participants were diagnosed with HSDD using validated diagnostic instruments including the Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale (FSDS-R). The study duration was 24 weeks, with subjects receiving either bremelanotide 1.75 mg SC or placebo prior to anticipated sexual activity — up to one dose per 24 hours, maximum 8 doses per 30 days.
Primary endpoints and results
The FDA evaluated two co-primary endpoints: change from baseline in the FSDS-R Item 13 score (distress related to low sexual desire) and change from baseline in the Female Sexual Function Index desire domain.
Results from the pooled analysis:
- Desire domain (FSFI): Bremelanotide improved desire scores by a mean of 0.30 points more than placebo (statistically significant, p<0.0001)
- Distress score (FSDS-R Item 13): Bremelanotide reduced distress by a mean of 0.30 points more than placebo (statistically significant, p<0.0001)
- Responder rate: Approximately 24.5% of participants on bremelanotide were classified as responders vs. ~17% in the placebo group — a meaningful but modest treatment effect
- Satisfying sexual events: A secondary endpoint showed bremelanotide increased the number of satisfying sexual events per 28-day period versus placebo
A 24% responder rate vs. 17% placebo may appear modest. The absolute difference is about 7–8 percentage points. This is not unusual for CNS-targeting medications in conditions with substantial placebo response. The clinical significance should be interpreted in the context of a condition where validated treatment options are extremely limited — for women with meaningful HSDD-related distress, even a modest pharmacological effect can represent a significant quality-of-life improvement.
What the trials didn't measure
The RECONNECT trials enrolled exclusively premenopausal women with acquired, generalized HSDD. There is limited RCT evidence for bremelanotide in postmenopausal women, women with situational HSDD (caused by relationship factors or specific circumstances), or women with other sexual dysfunction diagnoses such as female sexual arousal disorder (FSAD) or orgasmic disorder. Off-label use in these populations occurs clinically but is not supported by robust controlled trial data.
Off-Label Use in Men: What the Evidence Shows
PT-141's story actually began with men — specifically, the accidental observation that melanocortin agonists induced erections in male research participants. That observation launched the original development program, which was subsequently deprioritized after the blood pressure findings triggered the FDA clinical hold.
Phase 2 trial data for erectile dysfunction
Before the pivot to female sexual dysfunction, Palatin conducted two Phase 2 randomized controlled trials of intranasal bremelanotide in men with erectile dysfunction. Results published in the Journal of Urology showed:
- Statistically significant improvement in erectile function scores vs. placebo
- Benefit was most pronounced in men with psychogenic or mixed-etiology ED
- Effect in purely vasculogenic ED was less consistent
- The compound was not tested as a direct competitor to PDE5 inhibitors — it was evaluated for men who did not respond to or tolerate sildenafil
Why it wasn't approved for men
The primary reason the male ED program was discontinued was not lack of efficacy — it was the blood pressure concern. Intranasal delivery produced greater variability in plasma concentration and more pronounced cardiovascular effects than the subcutaneous formulation later used for the female program. The company made a strategic decision not to pursue the male indication rather than a finding of inefficacy.
Current off-label use in men
Many men use PT-141 off-label for two primary reasons:
- As an adjunct to PDE5 inhibitors: Some men find that combining PT-141 (central desire activation) with a PDE5 inhibitor (peripheral blood flow) produces synergistic results, particularly when the ED has a psychological or mixed component.
- For low libido or desire disorders: Men experience low sexual desire too, and testosterone is not always the answer. PT-141's central mechanism makes it theoretically applicable regardless of hormone levels.
Off-label use in men is based on Phase 2 trial data from intranasal bremelanotide, clinical case series, and anecdotal reports — not the same level of evidence as the Phase 3 RCT data supporting the FDA-approved female indication. A prescribing physician should weigh this when making treatment decisions.
Nasal Spray vs. Injection: The Delivery Debate
This is one of the most persistent points of confusion in the PT-141 space. Here's what actually happened, and what it means for how the compound is used today.
Why the nasal spray was abandoned
PT-141 was originally developed and tested as an intranasal spray, and early trial data in both men and women showed clear efficacy signals. The problem was pharmacokinetic variability. Intranasal drug delivery is highly sensitive to nasal mucosal conditions, individual anatomy, and administration technique. The resulting variability in absorption meant inconsistent plasma concentrations — and unpredictable cardiovascular effects (primarily transient blood pressure increases).
This blood pressure concern led the FDA to place a clinical hold on the intranasal program in 2007. The hold was not based on a catastrophic safety event — it was a precautionary response to a pattern of modest but consistent blood pressure elevations in a condition-specific population where cardiovascular risk management is important.
The injectable formulation's advantage
Subcutaneous injection — the delivery method used in Vyleesi — offers substantially more predictable pharmacokinetics. Fixed dosing via SC injection bypasses the mucosal variability problem, produces more consistent peak plasma concentrations, and generates a more controlled blood pressure profile (the increase is present but more predictable and monitorable).
The FDA-approved product is a single-use autoinjector pen, 1.75 mg SC, injected into the abdomen or thigh. The auto-injector design minimizes user administration error.
What about compounded nasal sprays available today?
Compounding pharmacies do offer PT-141 in intranasal formulations, typically at lower price points than Vyleesi. These are not FDA-approved. The pharmacokinetic variability concerns that contributed to the clinical hold remain relevant. If you're considering this route, the relevant questions are: Is the compounding pharmacy PCAB-accredited? What quality testing does the product undergo? Has your provider reviewed the cardiovascular implications?
This isn't a categorical condemnation — compounded medications serve important access functions. It's a calibration of evidence quality and risk awareness.
Side Effects, Safety, and Blood Pressure
Bremelanotide's side effect profile is well-characterized from the RECONNECT trials and post-marketing experience. The compound is generally well-tolerated in the approved population, with most side effects being transient and predictable — but there are meaningful considerations that require informed discussion before use.
Common side effects (≥5% incidence in trials)
- Nausea: The most common side effect, occurring in approximately 40% of users in clinical trials. Severity varies from mild to significant. Most episodes are transient (1–2 hours after dosing). Pretreatment with antiemetics (ondansetron, promethazine) substantially reduces incidence and severity.
- Flushing: Approximately 20% of users experience warmth and redness, primarily in the face and chest. The effect is transient and generally mild.
- Injection site reactions: Bruising, redness, and localized pain at the injection site occur in approximately 13–17% of users. Rotating injection sites reduces incidence.
- Headache: Reported in approximately 11% of users. Typically mild and self-limiting.
- Fatigue and somnolence: Mild sedation reported in some users, consistent with the compound's central mechanism.
The blood pressure question
Bremelanotide causes a transient increase in blood pressure following injection — typically 6–8 mmHg systolic and 3–4 mmHg diastolic, peaking within the first 2 hours and returning to baseline by 8–12 hours. This effect was the central reason for earlier development delays and is explicitly addressed in the drug's prescribing information.
Vyleesi is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease. The labeling also notes that use within 24 hours of certain antihypertensive medications may complicate blood pressure management. This is not a casual footnote — it is a meaningful safety consideration that requires honest cardiovascular assessment before prescribing.
Transient hyperpigmentation
A less commonly discussed side effect is focal hyperpigmentation — darkening of the face, breast, or gums — occurring in approximately 1% of users in trials. This is mediated by MC1R activation in melanocytes and is distinct from the desired central effects. The effect is typically reversible on discontinuation but may take months to resolve with repeated use.
WHAT WORKS IN ITS FAVOR
- FDA-approved for a real, validated indication
- Central mechanism addresses desire directly
- As-needed — no daily commitment
- Effects are acute and reversible
- Can be used alongside other therapies
- Antiemetics substantially reduce nausea
MEANINGFUL LIMITATIONS
- Nausea rate is high (~40%) without antiemetics
- Contraindicated in cardiovascular disease or uncontrolled hypertension
- Modest responder rates in clinical trials
- Expensive; limited insurance coverage
- Injection delivery is a barrier for some users
- Hyperpigmentation possible with repeated use
Cost, Access, and Who Qualifies
Cost is the most frequently cited barrier to Vyleesi access in the United States, and the insurance coverage landscape remains complicated.
List price and insurance coverage
Vyleesi's list price is approximately $900–$1,000 per month (4 autoinjector pens, typically a one-month supply) without insurance. Insurance coverage varies significantly by payer. Many commercial plans cover FDA-approved sexual dysfunction treatments, but coverage for Vyleesi specifically — as opposed to Addyi — is inconsistent. Pre-authorization requirements, step therapy protocols (requiring Addyi trial first), and quantity limits are common barriers.
Manufacturer assistance programs exist. Covis Pharma has historically offered a savings card program for commercially insured patients. Check the official Vyleesi prescribing site for current assistance options.
Who qualifies under the FDA indication
The formal indication is specific: acquired (not lifelong), generalized HSDD in premenopausal women. Diagnosis typically requires:
- A validated clinical assessment (FSFI score, FSDS-R Item 13 scoring)
- Exclusion of relationship or contextual factors as the primary cause
- Confirmation that the desire deficit causes personal distress
- Normal or above-threshold hormonal workup (the condition should not be better explained by low testosterone, thyroid dysfunction, or menopause)
- Absence of contraindications (cardiovascular disease, uncontrolled hypertension)
Compounded PT-141: The access alternative
Compounding pharmacies offer PT-141 at significantly lower price points — typically $100–$300 per vial, with cost varying by dose and quantity. This makes PT-141 accessible to a broader population, including men and postmenopausal women not covered by the FDA indication, and individuals for whom the cost of Vyleesi is prohibitive.
Quality and regulatory status vary by pharmacy. The FDA has issued guidance on compounding of drugs with approved equivalents. Patients using compounded PT-141 should ensure their pharmacy is PCAB-accredited and that the compound has undergone appropriate sterility and potency testing.
Sexual Wellness as a Longevity Signal
The medicalization of sexual wellness — and specifically the development of pharmacological interventions like PT-141 — sits within a broader conversation about what we consider essential to health across the lifespan. This framing matters.
Sexual function is not simply a quality-of-life variable. It is a biomarker of systemic health. Erectile function is one of the most sensitive early indicators of cardiovascular disease in men. Female sexual dysfunction often reflects underlying hormonal imbalance, pelvic floor dysfunction, or mood disorders that warrant clinical attention independent of sexual outcomes. The decline of sexual interest with age — while culturally normalized — is not inevitable, and it frequently correlates with declines in other health parameters.
The longevity medicine community is increasingly recognizing this. Sexual health is now included in most comprehensive longevity assessments, and addressing desire disorders is seen as part of a broader commitment to vitality and wellbeing rather than an isolated, stigmatized clinical concern.
PT-141's significance in this context is its direct targeting of the desire circuit — the motivational component of sexual engagement. When low desire is not secondary to another condition (hormonal imbalance, medication side effects, depression) but is the primary clinical finding, PT-141 represents one of the very few pharmacological tools designed specifically for that neurological endpoint.
We cover the broader landscape of sexual wellness as a health pillar in our editorial Sexual Wellness & Peptides: Libido, Hormones & What Science Actually Supports, which addresses the full range of pharmaceutical, peptide, and lifestyle-based approaches.
Honest Verdict
A genuinely novel mechanism. Meaningful but modest efficacy. Worth knowing about.
PT-141/bremelanotide is a real FDA-approved medication with a compelling and genuinely unique mechanism of action. It targets the desire circuitry directly — not blood flow, not hormones, not mood neurotransmitters — and that is pharmacologically significant. For women with acquired, generalized HSDD who have been evaluated by a provider and meet the indication, it represents a legitimate option that doesn't exist anywhere else in the approved pharmacopoeia.
The limitations are real too. A 24% responder rate vs. 17% placebo is statistically significant but clinically modest. Nausea in 40% of users is a meaningful burden (reduced substantially with antiemetics). The cardiovascular contraindications are serious and not to be ignored. Cost and insurance barriers are considerable in the US market.
For men and postmenopausal women, the evidence base is thinner — Phase 2 trials and clinical experience rather than Phase 3 RCTs. That's not disqualifying, but it's honest context.
Where PT-141 earns genuine respect is in what it represents: the first class of treatments to address the neural desire circuit directly. The science of central sexual neuropharmacology is young. PT-141 is a first-generation compound in a space that will almost certainly see more development. Knowing it exists, how it works, and what to expect is worth your attention regardless of whether it's your answer.
Who should discuss PT-141 with a provider?
- Premenopausal women with distressing, persistent low sexual desire that is not explained by a hormonal imbalance, medication side effect, or relationship context
- Women who have not found adequate benefit from Addyi or prefer an as-needed option
- Men with low libido or ED with a psychogenic or mixed component who are not fully served by PDE5 inhibitors alone
- Anyone in whom the cardiovascular contraindications have been clearly evaluated and excluded
Who should not
- Anyone with uncontrolled hypertension or known cardiovascular disease
- Those currently taking antihypertensive medications without careful provider supervision of the timing interaction
- Those who are pregnant or may become pregnant (teratogenicity risks require evaluation)
- Anyone seeking a self-prescribed solution without a proper clinical evaluation of the underlying cause of desire dysfunction
For a broader look at the peptide landscape related to sexual wellness and hormone optimization, see the WellSourced Peptide Library, which includes a full profile on PT-141/bremelanotide alongside other compounds studied for related outcomes.